News | July 24, 2025
Pfizer completes licensing agreement with 3SBio to expand oncology portfolio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
The unique soap-fusion of Gondhoraj lime and neem provides a refreshing skin-friendly experience
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
The trademark rights for these brands will be transferred to Lupin by March next year.
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Subscribe To Our Newsletter & Stay Updated
